(Q35737102)

10 August 2017

1 reference

title

Drug-induced pulmonary infection (English)

1 reference

10 August 2017

Dorothy A White

1

1 reference

10 August 2017

publication date

1 March 2004

1 reference

Clinics in Chest Medicine

10 August 2017

published in

1 reference

10 August 2017

volume

25

1 reference

10 August 2017

issue

1

1 reference

10 August 2017

page(s)

179-187

1 reference

Glucocorticoids and inflammation revisited: the state of the art. NIH clinical staff conference

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Anti-inflammatory actions of glucocorticoids: molecular mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Risk of infectious complications in patients taking glucocorticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Wegener Granulomatosis: An Analysis of 158 Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Peripheral blood CD4 + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Epidemiology ofAspergillusInfections in a Large Cohort of Patients Undergoing Bone Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Pathogenesis of pulmonary aspergillosis. Granulocytopenia versus cyclosporine and methylprednisolone-induced immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Aspergillosis case-fatality rate: systematic review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Tuberculosis after corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Tuberculosis in immunosuppressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Mycobacterial infections in immunosuppressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Tuberculosis complicating neoplastic disease.A review of 201 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Infectious complications of immunosuppressive therapy in patients with rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Cryptococcosis associated with low-dose methotrexate for arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Nocardia asteroides pneumonia complicating low dose methotrexate treatment of refractory rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Opportunistic infection during treatment with low dose methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Does methotrexate increase the risk of infection or malignancy?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Clinical trial of tacrolimus versus cyclosporine in lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Reactivation of histoplasmosis after treatment with infliximab

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Tumor necrosis factor-alpha antagonists for the treatment of rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Infectious and immunosuppressive complications of purine analog therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Severe immunodeficiency in patients treated with fludarabine monophosphate

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Infections in patients with chronic lymphocytic leukemia treated with fludarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Quantification of CMV viraemia in a case of transfusion-related graft-versus-host disease associated with purine analogue treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Infectious complications after 2-chlorodeoxyadenosine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Phase I/II evaluation of pentostatin (2'-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Infection and immunity in chronic lymphocytic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900134-5

7 January 2021

10.1016/S0272-5231(03)00134-5

Identifiers

DOI

1 reference

10 August 2017

1 reference